- Home
- TGTX vs ACIW Comparison
TGTX vs ACIW Comparison
Compare TGTX & ACIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- ACIW
- Stock Information
- Founded
- TGTX 1993
- ACIW 1975
- Country
- TGTX United States
- ACIW United States
- Employees
- TGTX N/A
- ACIW N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- ACIW EDP Services
- Sector
- TGTX Health Care
- ACIW Technology
- Exchange
- TGTX Nasdaq
- ACIW Nasdaq
- Market Cap
- TGTX 5.5B
- ACIW 5.3B
- IPO Year
- TGTX 1995
- ACIW 1995
- Fundamental
- Price
- TGTX $32.18
- ACIW $49.42
- Analyst Decision
- TGTX Strong Buy
- ACIW Strong Buy
- Analyst Count
- TGTX 5
- ACIW 3
- Target Price
- TGTX $48.20
- ACIW $60.00
- AVG Volume (30 Days)
- TGTX 1.8M
- ACIW 674.9K
- Earning Date
- TGTX 11-03-2025
- ACIW 11-06-2025
- Dividend Yield
- TGTX N/A
- ACIW N/A
- EPS Growth
- TGTX N/A
- ACIW 16.89
- EPS
- TGTX 2.78
- ACIW 2.47
- Revenue
- TGTX $531,898,000.00
- ACIW $1,731,220,000.00
- Revenue This Year
- TGTX $82.31
- ACIW $10.58
- Revenue Next Year
- TGTX $49.05
- ACIW $6.86
- P/E Ratio
- TGTX $11.61
- ACIW $19.79
- Revenue Growth
- TGTX 100.88
- ACIW 7.01
- 52 Week Low
- TGTX $25.28
- ACIW $40.45
- 52 Week High
- TGTX $46.48
- ACIW $59.71
- Technical
- Relative Strength Index (RSI)
- TGTX 39.20
- ACIW 49.29
- Support Level
- TGTX $31.07
- ACIW $46.61
- Resistance Level
- TGTX $34.74
- ACIW $52.28
- Average True Range (ATR)
- TGTX 1.70
- ACIW 1.35
- MACD
- TGTX -0.27
- ACIW 0.09
- Stochastic Oscillator
- TGTX 17.74
- ACIW 49.56
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About ACIW ACI Worldwide Inc.
ACI Worldwide Inc develops, markets and installs a portfolio of software products focused on facilitating electronic payments. The firm also leverages its distribution network in the Americas; Europe, the Middle East, and Africa, or EMEA; and Asia-Pacific regions to sell software developed by third parties. ACI software products process payment transactions for retail banking clients, billers such as utilities and healthcare providers, and community banks and credit unions. ACI's customers are financial institutions all over the world, but majority of the revenue is generated in the United States and EMEA regions.